Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Authors
Keywords
-
Journal
Nature Reviews Endocrinology
Volume 16, Issue 10, Pages 556-577
Publisher
Springer Science and Business Media LLC
Online
2020-08-27
DOI
10.1038/s41574-020-0392-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
- (2020) A.J. Scheen DIABETES & METABOLISM
- Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease
- (2020) André J. Scheen CLINICAL PHARMACOKINETICS
- Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
- (2019) David Fitchett et al. CIRCULATION
- Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
- (2019) Radica Z. Alicic et al. DIABETES
- Dapagliflozin and Cardiovascular Mortality and Disease Outcomes in Type 2 Diabetes Patients Similar to the DECLARE-TIMI 58 Participants: A Nationwide Observational Study
- (2019) Anna Norhammar et al. DIABETES OBESITY & METABOLISM
- Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis
- (2019) Tamara Milder et al. Journal of Clinical Medicine
- Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-Analysis
- (2019) Binayak Sinha et al. Diabetes Therapy
- Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
- (2019) Jennifer R Donnan et al. BMJ Open
- Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy
- (2019) Riobaldo Cintra et al. Revista da Associacao Medica Brasileira
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary
- (2019) Donna K. Arnett et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System
- (2019) Tuba M. Ansary et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline
- (2019) James Januzzi et al. EUROPEAN JOURNAL OF HEART FAILURE
- Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
- (2019) Maria J. Pereira et al. DRUGS
- Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
- (2019) David R. Matthews et al. DIABETOLOGIA
- Uric acid and the cardio‐renal effects of SGLT2 inhibitors
- (2019) Clifford J. Bailey DIABETES OBESITY & METABOLISM
- Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis
- (2019) Tadashi Toyama et al. DIABETES OBESITY & METABOLISM
- Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial
- (2019) Silvio E. Inzucchi et al. DIABETES CARE
- Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis
- (2019) Hillel Sternlicht et al. CURRENT HYPERTENSION REPORTS
- Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial
- (2019) Remo H. M. Furtado et al. CIRCULATION
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
- (2019) Eri T. Kato et al. CIRCULATION
- Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of MajorAdverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials
- (2019) Thomas A. Zelniker et al. CIRCULATION
- Antihyperglycemic and Blood Pressure Effects of Empagliflozin in African Americans with Type 2 Diabetes and Hypertension
- (2019) Keith C. Ferdinand et al. CIRCULATION
- Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality
- (2019) Gianluigi Savarese et al. CIRCULATION
- Minimizing Hyperglycemia-Induced Vascular Endothelial Dysfunction by Inhibiting Endothelial Sodium-Glucose Cotransporter 2 and Attenuating Oxidative Stress: Implications for Treating Individuals With Type 2 Diabetes
- (2019) Vivek Krishna Pulakazhi Venu et al. Canadian Journal of Diabetes
- Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors
- (2019) Susan J. Bersoff-Matcha et al. ANNALS OF INTERNAL MEDICINE
- Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy
- (2019) Anja Schork et al. Cardiovascular Diabetology
- Navigating the “MACE” in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits
- (2019) Christopher Hupfeld et al. DIABETES OBESITY & METABOLISM
- Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials
- (2019) Dario Giugliano et al. DIABETES OBESITY & METABOLISM
- Effects of sodium glucose cotransporter type 2 inhibitors on heart failure
- (2019) Michael E. Nassif et al. DIABETES OBESITY & METABOLISM
- A safety update on sodium glucose co‐transporter 2 inhibitors
- (2019) David Fitchett DIABETES OBESITY & METABOLISM
- A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium‐glucose co‐transporter‐2 inhibitors
- (2019) Emily Brown et al. DIABETES OBESITY & METABOLISM
- Acute kidney injury with sodium‐glucose co‐transporter‐2 inhibitors: A meta‐analysis of cardiovascular outcome trials
- (2019) Richard E. Gilbert et al. DIABETES OBESITY & METABOLISM
- Series: Implications of the recent CVOTs in type 2 diabetes
- (2019) André J. Scheen DIABETES RESEARCH AND CLINICAL PRACTICE
- Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
- (2019) Hiddo J. L. Heerspink et al. DIABETOLOGIA
- An update on the safety of SGLT2 inhibitors
- (2019) André J Scheen Expert Opinion On Drug Safety
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
- (2019) Jaime A Davidson POSTGRADUATE MEDICINE
- Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial
- (2019) Mark E. Cooper et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections
- (2019) Chintan V. Dave et al. ANNALS OF INTERNAL MEDICINE
- Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects
- (2019) Motoaki Sano et al. CIRCULATION
- Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial
- (2019) Kenneth W. Mahaffey et al. CIRCULATION
- Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus
- (2019) Joanna Sophia J. Vinke et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials
- (2019) Robert D. Toto et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- A Potential Mechanism of Cardio-Renal Protection with Sodium-Glucose Cotransporter 2 Inhibitors: Amelioration of Renal Congestion
- (2019) Satoru Kuriyama KIDNEY & BLOOD PRESSURE RESEARCH
- Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus
- (2019) Miao Feng et al. MEDICINE
- Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure
- (2019) André J. Scheen Current Cardiology Reports
- Effects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors
- (2019) Mie K. Eickhoff et al. Journal of Clinical Medicine
- Effects of sodium‐glucose cotransporter‐2 inhibitors on the cardiovascular and renal complications of type 2 diabetes
- (2019) Robert J. Chilton DIABETES OBESITY & METABOLISM
- Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
- (2019) Claire C. J. Dekkers et al. DIABETES OBESITY & METABOLISM
- Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
- (2019) Zien Zhou et al. DIABETOLOGIA
- 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2019) Francesco Cosentino et al. EUROPEAN HEART JOURNAL
- Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program
- (2019) Brendon L. Neuen et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases
- (2019) Lu Wang et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- An update on efficacy and safety of SGLT2 inhibitors in Asians and non‐Asians
- (2019) Yoshihito Fujita et al. Journal of Diabetes Investigation
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- (2019) Brendon L Neuen et al. Lancet Diabetes & Endocrinology
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c
- (2019) Christopher P. Cannon et al. CIRCULATION
- Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF
- (2019) Felipe A. Martinez et al. CIRCULATION
- Challenging 2019 ESC guidelines for the management of type 2 diabetes
- (2019) A.J. Scheen DIABETES & METABOLISM
- Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors
- (2019) Gian Paolo Fadini et al. BMJ Open Diabetes Research & Care
- Renal effects of SGLT2 inhibitors
- (2019) Josselin Nespoux et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETOLOGIA
- SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials
- (2018) Robert Puckrin et al. ACTA DIABETOLOGICA
- Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program
- (2018) Brendon L. Neuen et al. CIRCULATION
- Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
- (2018) Karin Rådholm et al. CIRCULATION
- Cardiovascular Effects of New Oral Glucose-Lowering Agents
- (2018) André J. Scheen CIRCULATION RESEARCH
- SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management
- (2018) Michaël J.B. van Baar et al. DIABETES CARE
- SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis
- (2018) Dandan Li et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis
- (2018) Man Guo et al. DIABETES OBESITY & METABOLISM
- Observational research on sodium glucose co-transporter 2 inhibitors: a real breakthrough?
- (2018) Emanuel Raschi et al. DIABETES OBESITY & METABOLISM
- Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists
- (2018) André J. Scheen DIABETES RESEARCH AND CLINICAL PRACTICE
- Are the favorable cardiovascular outcomes of empagliflozin treatment explained by its effects on multiple cardiometabolic risk factors? A simulation of the results of the EMPA-REG OUTCOME trial
- (2018) Shihchen Kuo et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
- (2018) Beatrice C. Lupsa et al. DIABETOLOGIA
- SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
- (2018) Christoph Wanner et al. DIABETOLOGIA
- The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus
- (2018) Hadi Fattah et al. DRUGS
- Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis
- (2018) Jian Li et al. ENDOCRINE JOURNAL
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2018) Marian Sue Kirkman et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
- (2018) Petar M. Seferović et al. EUROPEAN JOURNAL OF HEART FAILURE
- Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
- (2018) Hussein Al Jobori et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
- (2018) David Fitchett et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
- (2018) Mikhail Kosiborod et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
- (2018) Hiddo J.L. Heerspink et al. KIDNEY INTERNATIONAL
- Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes
- (2018) W. Timothy Garvey et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Does lower limb amputation concern all SGLT2 inhibitors?
- (2018) André J. Scheen Nature Reviews Endocrinology
- Adverse effects of SGLT2 inhibitors on bone health
- (2018) Jenny E. Blau et al. Nature Reviews Nephrology
- SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis
- (2018) Samuel Seidu et al. Primary Care Diabetes
- SGLT2 Inhibitors and Mechanisms of Hypertension
- (2018) Alexandros Briasoulis et al. Current Cardiology Reports
- Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
- (2018) Bernhard Ludvik et al. Lancet Diabetes & Endocrinology
- Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
- (2018) Atsutaka Yasui et al. Diabetes Therapy
- Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
- (2018) Atsutaka Yasui et al. Diabetes Therapy
- Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety CardioVascular outcomes trial (VERTIS-CV)
- (2018) Christopher P. Cannon et al. AMERICAN HEART JOURNAL
- Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease
- (2018) Fabrice Bonnet et al. DIABETES & METABOLISM
- Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial
- (2018) Serge A. Jabbour et al. DIABETES CARE
- Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?
- (2018) Francesco Prattichizzo et al. DIABETES OBESITY & METABOLISM
- Acute renal outcomes with SGLT-2 inhibitors - real world data analysis
- (2018) Avivit Cahn et al. DIABETES OBESITY & METABOLISM
- Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways
- (2018) Habib Yaribeygi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2018) Aidin Rawshani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms
- (2018) P. C. Lee et al. Obesity Reviews
- Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies
- (2018) Ken Lee Chin et al. CARDIOVASCULAR RESEARCH
- Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease
- (2018) Brian Claggett et al. CIRCULATION
- Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control
- (2018) Silvio E. Inzucchi et al. CIRCULATION
- Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis
- (2018) Maarten A. de Jong et al. Clinical Journal of the American Society of Nephrology
- Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes
- (2018) A.J. Scheen DIABETES & METABOLISM
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETES CARE
- How Representative are the Patients Included in the CV outcome Trials with SGLT2 Inhibitors of a General Type 2 Diabetes Population? A Large European Observational study
- (2018) K.I. Birkeland et al. DIABETES OBESITY & METABOLISM
- Why not adding a glucose-lowering agent with proven cardioprotection in high-risk patients with type 2 diabetes at HbA1c target on metformin?
- (2018) André J. Scheen DIABETES RESEARCH AND CLINICAL PRACTICE
- Preventing and treating kidney disease in patients with type 2 diabetes
- (2018) Pierre Delanaye et al. EXPERT OPINION ON PHARMACOTHERAPY
- Sodium-glucose cotransporter inhibitors and oxidative stress: An update
- (2018) Habib Yaribeygi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
- (2018) Michael S. Kelly et al. POSTGRADUATE MEDICINE
- Canagliflozin and Stroke in Type 2 Diabetes Mellitus
- (2018) Zien Zhou et al. STROKE
- Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
- (2018) Peter Ueda et al. BMJ-British Medical Journal
- Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
- (2017) David Fitchett et al. EUROPEAN HEART JOURNAL
- The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors
- (2017) Javed Butler et al. EUROPEAN JOURNAL OF HEART FAILURE
- SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database
- (2017) Abdel Nasser Ado Moumouni et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus
- (2017) Takahiro Kambara et al. Geriatrics & Gerontology International
- Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus
- (2017) Matthew J. Budoff et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels
- (2017) Harold E. Bays et al. Journal of Clinical Lipidology
- Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype
- (2017) Lee Ling Lim et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials
- (2017) Faramarz Ismail-Beigi et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor
- (2017) Michael Fralick et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes
- (2017) Jennifer M. Trujillo et al. PHARMACOTHERAPY
- SGLT2 inhibitor/DPP-4 inhibitor combination therapy – complementary mechanisms of action for management of type 2 diabetes mellitus
- (2017) Jayant Dey POSTGRADUATE MEDICINE
- Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
- (2017) Bernard Zinman et al. STROKE
- Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients
- (2017) Mohsen Mazidi et al. Journal of the American Heart Association
- The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study
- (2017) Christian Bommer et al. Lancet Diabetes & Endocrinology
- Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
- (2017) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure
- (2017) Milton Packer et al. JAMA Cardiology
- Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease
- (2017) Subodh Verma et al. CIRCULATION
- Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events
- (2017) Kenneth W. Mahaffey et al. CIRCULATION
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
- (2017) Christoph Wanner et al. CIRCULATION
- Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus
- (2016) Hiroyuki Tanaka et al. ADVANCES IN THERAPY
- Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus
- (2016) Huilin Tang et al. AMERICAN JOURNAL OF CARDIOLOGY
- Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
- (2016) Christian Sonesson et al. Cardiovascular Diabetology
- Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?
- (2016) Sanjay Kaul CIRCULATION
- Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
- (2016) Hiddo J.L. Heerspink et al. CIRCULATION
- SGLT2 Inhibitors: Benefit/Risk Balance
- (2016) André J. Scheen Current Diabetes Reports
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis
- (2016) André J. Scheen DIABETES & METABOLISM
- Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
- (2016) Sunder Mudaliar et al. DIABETES CARE
- Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013
- (2016) Kasia J. Lipska et al. DIABETES CARE
- SGLT2 Inhibitors and the Diabetic Kidney
- (2016) Paola Fioretto et al. DIABETES CARE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trials
- (2016) A. Salsali et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
- (2016) F. Zaccardi et al. DIABETES OBESITY & METABOLISM
- Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials
- (2016) Huilin Tang et al. DIABETES OBESITY & METABOLISM
- Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME
- (2016) André J. Scheen DIABETES RESEARCH AND CLINICAL PRACTICE
- Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
- (2016) Volker Vallon et al. DIABETOLOGIA
- Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials
- (2016) Huilin Tang et al. DIABETOLOGIA
- SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
- (2016) Naveed Sattar et al. DIABETOLOGIA
- Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?
- (2016) Edoardo Mannucci et al. DRUG SAFETY
- Efficacy and Safety of Canagliflozin in Patients With Type 2 Diabetes Mellitus of Different Ethnicity
- (2016) Jaime A. Davidson et al. ETHNICITY & DISEASE
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects
- (2016) André J. Scheen Expert Opinion on Drug Metabolism & Toxicology
- Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis
- (2016) Gianluigi Savarese et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
- (2016) Hiddo J. L. Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
- (2016) Ralph A. DeFronzo et al. Nature Reviews Nephrology
- Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus
- (2016) Thomas C. Blevins et al. POSTGRADUATE MEDICINE
- SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
- (2016) Deepson S Shyangdan et al. BMJ Open
- Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic β -cell function and reduction of insulin resistance
- (2016) Hideaki Kaneto et al. Journal of Diabetes
- Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
- (2016) Juan P Frías et al. Lancet Diabetes & Endocrinology
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
- (2016) Jason H Y Wu et al. Lancet Diabetes & Endocrinology
- An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients
- (2016) Zengqi Wang et al. Therapeutics and Clinical Risk Management
- The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
- (2015) Volker Vallon Annual Review of Medicine
- Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
- (2015) André J. Scheen CLINICAL PHARMACOKINETICS
- Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes
- (2015) C David Sjöström et al. Diabetes & Vascular Disease Research
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Anne L. Peters et al. DIABETES CARE
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
- (2015) Julio Rosenstock et al. DIABETES CARE
- Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes
- (2015) G. Fulcher et al. DIABETES OBESITY & METABOLISM
- SGLT2 Inhibitors May Predispose to Ketoacidosis
- (2015) Simeon I. Taylor et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sodium–glucose cotransporter-2 inhibitors and blood pressure decrease
- (2015) Konstantinos P. Imprialos et al. JOURNAL OF HYPERTENSION
- SGLT2 inhibitors: their potential reduction in blood pressure
- (2015) George Maliha et al. Journal of the American Society of Hypertension
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Excess Mortality among Persons with Type 2 Diabetes
- (2015) Mauro Tancredi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of Sodium-Glucose Cotransporter Type 2 Inhibitors in Older Adults with Type 2 Diabetes Mellitus
- (2015) Nasser Mikhail SOUTHERN MEDICAL JOURNAL
- Understanding EMPA-REG OUTCOME
- (2015) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- Possible adverse effects of SGLT2 inhibitors on bone
- (2015) Simeon I Taylor et al. Lancet Diabetes & Endocrinology
- Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)
- (2014) Matthew R. Weir et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal
- (2014) A.J. Scheen et al. DIABETES & METABOLISM
- Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence
- (2014) A.J. Scheen et al. DIABETES & METABOLISM
- Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis
- (2014) A. Liakos et al. DIABETES OBESITY & METABOLISM
- Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus
- (2014) S. Sha et al. DIABETES OBESITY & METABOLISM
- Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: Systematic review and meta-analyses
- (2014) Qian Zhang et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
- (2014) André J. Scheen DRUGS
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis
- (2014) Xu-Ping Yang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
- (2014) William L. Baker et al. Journal of the American Society of Hypertension
- Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
- (2014) Raymond V. Oliva et al. Journal of the American Society of Hypertension
- Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data
- (2014) Sarah Bujac et al. Diabetes Therapy
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
- (2013) EUROPEAN HEART JOURNAL
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
- (2011) Muhammad A. Abdul-Ghani et al. ENDOCRINE REVIEWS
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
- (2008) J. F. List et al. DIABETES CARE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now